How do you utilize JAK inhibitors for alopecia in the pediatric population?

There is little difference about counseling between adolescents (lowest age group approved) and adults, but the greater concern is really understanding the risks, especially given that the lifetime duration on the medication is likely going to be longer in an adolescent vs an adult -- and we know that stopping the medication probably would lead to hair loss again in someone with severe enough alopecia to start a JAK inhibitor. This said, all of the same issues need to be addressed -- including details about the boxed warning, with the caveat that young people tend to be healthier and to date have not shown the issues of concern in the boxed warning. But safety concerns loom large in this population and need full disclosure with monitoring t...

In the pediatric population, JAK inhibitors can be an appropriate treatment for alopecia areata, and ritlecitinib is approved for adolescents 12 years and older. Counseling on the use of JAK inhibitors requires an in-depth conversation about potential risks, including those identified by the FDA in the label, as well as risks that are currently unknown with the long-term use of JAK inhibitors in this population. Given that JAK inhibitors have generally been demonstrated to be safe for use over the course of a few years, I typically discuss thinking about treatment in terms of that time frame, with the idea that there may be other treatment approaches available at that time, and there will certainly be more data available on longer-term use.